Skip to content

Study · Animal study (in vivo) · mouse · 2016

10 results

Chronic Treatment with the AMPK Agonist AICAR Prevents Skeletal Muscle Pathology but Fails to Improve Clinical Outcome in a Mouse Model of Severe Spinal Muscular Atrophy.

Cerveró C, Montull N, Tarabal O, Piedrafita L, Esquerda JE, Calderó J

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics1 Jan 2016Cited by 30 (Europe PMC)

PMID26582176 (opens in a new tab)PMCIDPMC4720671 (opens in a new tab)DOI10.1007/s13311-015-0399-x (opens in a new tab)PepBankPUB-26582176
Source linkPubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In SMNΔ7 mice, AICAR improved skeletal muscle atrophy.

    In plain wordsIn mice with severe spinal muscular atrophy, AICAR reduced muscle wasting.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseSkeletal muscle atrophy
    Study

    mousen: not reported in source

    SMNΔ7 severe spinal muscular atrophy
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We report that AICAR improved skeletal muscle atrophy and structural changes found in neuromuscular junctions of SMNΔ7 animals.
    1 context sentence
    Summary · context
    Here, we investigated whether chronic AICAR treatment was able to elicit beneficial effects on motor abilities and neuromuscular histopathology in a mouse model of severe SMA (the SMNΔ7 mouse).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In SMNΔ7 mice, AICAR improved neuromuscular junction structural changes.

    In plain wordsIn mice with severe spinal muscular atrophy, AICAR improved nerve-muscle junction structure.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseNeuromuscular junction structural abnormalities
    Study

    mousen: not reported in source

    SMNΔ7 severe spinal muscular atrophy
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We report that AICAR improved skeletal muscle atrophy and structural changes found in neuromuscular junctions of SMNΔ7 animals.
    1 context sentence
    Summary · context
    Here, we investigated whether chronic AICAR treatment was able to elicit beneficial effects on motor abilities and neuromuscular histopathology in a mouse model of severe SMA (the SMNΔ7 mouse).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In SMNΔ7 mice, AICAR prevented loss of glutamatergic excitatory synapses on motor neurons.

    In plain wordsIn mice with severe spinal muscular atrophy, AICAR prevented loss of excitatory synapses on motor neurons.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseGlutamatergic excitatory synapse loss
    Study

    mousen: not reported in source

    SMNΔ7 severe spinal muscular atrophy
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, although AICAR prevented the loss of glutamatergic excitatory synapses on MNs, this compound was not able to mitigate MN loss or the microglial and astroglial reaction occurring in the spinal cord of diseased mice.
    1 context sentence
    Summary · context
    Here, we investigated whether chronic AICAR treatment was able to elicit beneficial effects on motor abilities and neuromuscular histopathology in a mouse model of severe SMA (the SMNΔ7 mouse).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In SMNΔ7 mice, AICAR did not mitigate motor neuron loss.

    In plain wordsIn mice with severe spinal muscular atrophy, AICAR did not reduce motor neuron loss.

    Peptide
    AICAR (acadesine)
    Outcome
    No significant changeMotor neuron loss
    Study

    mousen: not reported in source

    SMNΔ7 severe spinal muscular atrophy
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, although AICAR prevented the loss of glutamatergic excitatory synapses on MNs, this compound was not able to mitigate MN loss or the microglial and astroglial reaction occurring in the spinal cord of diseased mice.
    1 context sentence
    Summary · context
    Here, we investigated whether chronic AICAR treatment was able to elicit beneficial effects on motor abilities and neuromuscular histopathology in a mouse model of severe SMA (the SMNΔ7 mouse).
  5. 05AnimalAnimal study (in vivo)Mechanism

    In SMNΔ7 mice, AICAR did not mitigate spinal microglial reaction.

    In plain wordsIn mice with severe spinal muscular atrophy, AICAR did not reduce the spinal microglial reaction.

    Peptide
    AICAR (acadesine)
    Outcome
    No significant changeMicroglial reaction
    Study

    mousen: not reported in source

    SMNΔ7 severe spinal muscular atrophy
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, although AICAR prevented the loss of glutamatergic excitatory synapses on MNs, this compound was not able to mitigate MN loss or the microglial and astroglial reaction occurring in the spinal cord of diseased mice.
    1 context sentence
    Summary · context
    Here, we investigated whether chronic AICAR treatment was able to elicit beneficial effects on motor abilities and neuromuscular histopathology in a mouse model of severe SMA (the SMNΔ7 mouse).
  6. 06AnimalAnimal study (in vivo)Mechanism

    In SMNΔ7 mice, AICAR did not mitigate spinal astroglial reaction.

    In plain wordsIn mice with severe spinal muscular atrophy, AICAR did not reduce the spinal astroglial reaction.

    Peptide
    AICAR (acadesine)
    Outcome
    No significant changeAstroglial reaction
    Study

    mousen: not reported in source

    SMNΔ7 severe spinal muscular atrophy
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, although AICAR prevented the loss of glutamatergic excitatory synapses on MNs, this compound was not able to mitigate MN loss or the microglial and astroglial reaction occurring in the spinal cord of diseased mice.
    1 context sentence
    Summary · context
    Here, we investigated whether chronic AICAR treatment was able to elicit beneficial effects on motor abilities and neuromuscular histopathology in a mouse model of severe SMA (the SMNΔ7 mouse).
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In SMNΔ7 mice, AICAR did not improve survival.

    In plain wordsIn mice with severe spinal muscular atrophy, AICAR did not improve survival.

    Peptide
    AICAR (acadesine)
    Outcome
    No significant changeSurvival
    Study

    mousen: not reported in source

    SMNΔ7 severe spinal muscular atrophy
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, no improvement in survival or motor performance was seen in SMNΔ7 animals treated with AICAR.
    1 context sentence
    Summary · context
    Here, we investigated whether chronic AICAR treatment was able to elicit beneficial effects on motor abilities and neuromuscular histopathology in a mouse model of severe SMA (the SMNΔ7 mouse).
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In SMNΔ7 mice, AICAR did not improve motor performance.

    In plain wordsIn mice with severe spinal muscular atrophy, AICAR did not improve movement performance.

    Peptide
    AICAR (acadesine)
    Outcome
    No significant changeMotor performance
    Study

    mousen: not reported in source

    SMNΔ7 severe spinal muscular atrophy
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, no improvement in survival or motor performance was seen in SMNΔ7 animals treated with AICAR.
    1 context sentence
    Summary · context
    Here, we investigated whether chronic AICAR treatment was able to elicit beneficial effects on motor abilities and neuromuscular histopathology in a mouse model of severe SMA (the SMNΔ7 mouse).
  9. 09AnimalAnimal study (in vivo)Mechanism

    In SMNΔ7 mice, AICAR did not change spinal cord SMN protein expression.

    In plain wordsIn mice with severe spinal muscular atrophy, AICAR did not change spinal cord SMN protein expression.

    Peptide
    AICAR (acadesine)
    Outcome
    No significant changeSpinal cord SMN expression
    Study

    mousen: not reported in source

    SMNΔ7 severe spinal muscular atrophy
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The beneficial effects of AICAR in SMA found in our study are SMN-independent, as no changes in the expression of this protein were seen in the spinal cord and skeletal muscle of diseased animals treated with this compound.
    1 context sentence
    Summary · context
    Here, we investigated whether chronic AICAR treatment was able to elicit beneficial effects on motor abilities and neuromuscular histopathology in a mouse model of severe SMA (the SMNΔ7 mouse).
  10. 10AnimalAnimal study (in vivo)Mechanism

    In SMNΔ7 mice, AICAR did not change skeletal muscle SMN protein expression.

    In plain wordsIn mice with severe spinal muscular atrophy, AICAR did not change muscle SMN protein expression.

    Peptide
    AICAR (acadesine)
    Outcome
    No significant changeSkeletal muscle SMN expression
    Study

    mousen: not reported in source

    SMNΔ7 severe spinal muscular atrophy
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The beneficial effects of AICAR in SMA found in our study are SMN-independent, as no changes in the expression of this protein were seen in the spinal cord and skeletal muscle of diseased animals treated with this compound.
    1 context sentence
    Summary · context
    Here, we investigated whether chronic AICAR treatment was able to elicit beneficial effects on motor abilities and neuromuscular histopathology in a mouse model of severe SMA (the SMNΔ7 mouse).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.